Etid klinik pou Kansè san nan Washington
20 etid pou Kansè san ap chèche patisipan nan sit nan Washington.
Vil nan Washington
Tèks ofisyèl etid la (Anglè)
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
- Fred Hutchinson Cancer Center ( Site 0024), Bellevue
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT03486873Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Providence Regional Cancer System-Aberdeen, Aberdeen
- PeaceHealth Saint Joseph Medical Center, Bellingham
- Providence Regional Cancer System-Centralia, Centralia
- ak 19 plis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- Fred Hutchinson Cancer Research Center, Seattle
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06697184Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Medical Oncology Associates (Summit Cancer Centers) ( Site 2710), Spokane
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT04728893Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Fred Hutchinson Cancer Research Center, Seattle
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT07648264Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- Providence Regional Cancer System-Aberdeen, Aberdeen
- PeaceHealth Saint Joseph Medical Center, Bellingham
- Providence Regional Cancer System-Centralia, Centralia
- ak 18 plis
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Sep 17, 2026 · NCT04242095Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- University of Washington, Seattle
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT06001788Mobile Health Application (PACT) to Improve Engagement in Advance Care Planning
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Ap rekriteVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT04515810PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
- Fred Hutchinson Cancer Center, Seattle
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT06665100A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Fred Hutchinson Cancer Research Center, Seattle
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jul 6, 2026 · NCT01351545IVIG for Infection Prevention After CAR-T-Cell Therapy
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT05952804211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Ap rekriteFaz 1/2
Laj 18 a 75 · Tout sèks · Mizajou Jun 22, 2026 · NCT03670966Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy
- Seattle Childrens Hospital, Seattle
Ap rekriteEtid obsèvasyon
Jiska laj 30 · Tout sèks · Mizajou Jun 18, 2026 · NCT06579469CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- University of Washington Medical Center, Seattle
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Apr 16, 2026 · NCT03328078Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial
- Fred Hutchinson Cancer Centre, Seattle
Ap rekriteFaz 2Volontè an sante akeyi
Laj 2 ak plis · Tout sèks · Mizajou Apr 16, 2026 · NCT06510699A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
- Swedish Cancer Institute, Seattle
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jun 25, 2025 · NCT05768269PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma
- University of Washington, Seattle
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Apr 20, 2025 · NCT05956457Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
- Fred Hutchinson Cancer Center, Seattle
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 15, 2025 · NCT06462365Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Seattle Children's Hospital, Seattle
Ap rekriteFaz 1
Laj 1 a 21 · Tout sèks · Mizajou Dec 6, 2024 · NCT05476770Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- Fred Hutchinson Cancer Center, Seattle
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Nov 15, 2024 · NCT06034275Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.